PROPEL BIOLOGICS™ JetCAP™

Revolutionary Oral Capsule Device for Precision Delivery of Biologics

  • Needle-free fluid transport to gut wall
  • 10 - 30 mg per dose
  • Systemic delivery comparable to SC
  • Targeted region-specific GI delivery
  • Standard pharmaceutical components
  • Enteric coated - GRAS excipients
  • Low cost of goods
  • Liquid-fill manufacturing
Capsule Assy

*Device size is comparable to 000 Capsule Size

HOW JetCAP™ WORKS

ACTUATION: At a defined pH in the GI tract, enteric coated tablet and nozzle plugs dissolve, preparing the device for delivery of drug.

DEPLOYMENT: Dissolution of the tablet releases the spring, which pushes the plunger, delivering drug from the liquid-filled reservoir to the gut wall.

ELIMINATION: The fluid stream is delivered
at the defined depths to the gut wall. The expended capsule passes harmlessly in unopened state.

JetCAP(just diagram)

JetCAP™ vs. COMPETING TECHNOLOGIES

Bioavailability comparable to SC for all technologies

Dose Range Delivery Method Formulation
Baywind Bio: JetCap™ 10-30 mgs Needle free liquid transport to gut wall Solution or suspension
MIT: SOMA 1-5 mgs Microneedle spike injection Compressed microneedle
Rani: RaniPill™ 1-3 mgs Microneedle patch injection Sugar based microneedle

JetCAP™ ADVANTAGES

High drug delivery capacity

Common pharmaceutical components

Liquid-filled reservoir

  • 10 to 30 mg per day delivery
  • Potential for les frequent administration
  • Ultra-long acting oral product
  • Injection molded parts
  • Plunger and nozzle
  • Tablet actuation mechanism
  • Solution or suspension formulation
  • Rapidly adaptable from injectable product
  • Long-acting particulate suspensions
JetCAP™ RaniPill™ MIT SOMA
High Dose 10-30 mgs
Needle-Free
Extended-release Formulation
Standard Pharma Components
Liquid Fill Manufacture
Targeted GI Delivery
High Bioavailability
Oral Delivery of Biologics

JetCAP™ Patents Pending

  • “Capsule device for oral delivery of biologics” US appl 62/722,083 filed 08/23/2018
  • “Capsule device for delivery of active agent to gastro-intestinal tract” PCT/US19/48034 filed 08/23/2019, claims priority to the US filing date of 08/23/2018